Raymond James Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Raymond James Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16M	Sell	279,274 -52,099	-16%	-$2.85M	﹤0.01%	1739
2026 Q1	$18.7M	Buy	331,373 +120,075	+57%	+$7M	0.01%	1519
2025 Q4	$12.6M	Buy	211,298 +119,692	+131%	+$6.52M	﹤0.01%	1785
2025 Q3	$4.96M	Buy	91,606 +19,924	+28%	+$1.14M	﹤0.01%	2455
2025 Q2	$3.94M	Sell	71,682 -26,651	-27%	-$1.57M	﹤0.01%	2540
2025 Q1	$6.95M	Buy	98,333 +16,519	+20%	+$1.11M	﹤0.01%	2083
2024 Q4	$5.38M	Buy	+81,814	New	+$5.48M	﹤0.01%	2284

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Raymond James Financial's BMRN Position: Q2 2026 in Review

Raymond James Financial reduced its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q2 2026, selling an estimated $2.85M and leaving 279,274 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Raymond James Financial first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $18.7M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Raymond James Financial held 279,274 shares of BioMarin Pharmaceuticals worth $16M as of Q2 2026.
Raymond James Financial sold 52,099 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.85M.
BioMarin Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1739 holding.
Raymond James Financial first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's BioMarin Pharmaceuticals position peaked at $18.7M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.